Cancer Harboring BRAF Alterations clinical trials at UCSF

1 research study open to eligible people

Cancer with BRAF alterations means the BRAF gene has changed, leading to cancer growth. UCSF is conducting studies on plixorafenib to determine its effectiveness against such cancers. Safety of this treatment is also being evaluated in these trials.

Showing trials for

  • FORE8394 in Participants With Cancer Harboring BRAF Alterations

    open to eligible people ages 10 years and up

    The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare solid tumors, melanoma, thyroid, or recurrent primary CNS tumors harboring BRAF V600E mutation. This will be conducted as four open-label subprotocols (F8394-201A; F8394-201B; F8394-201C; F8394-201D) under one master protocol.

    San Francisco, California and other locations

Last updated: